Five months after the FDA approved Purdue Pharma's opioid antagonist injection, nalmefene hydrochloride, the no-profit treatment is now available for use, according to a June 21 press release.
Nalmefene hydrochloride is for a "complete or partial reversal of opioid drug effects," such as respiratory depression, the press release said.